Inhaled insulin is effective for controlling blood sugar levels in children with diabetes, providing them with a ...

Hims and Hers announced this morning that it will begin offering compounded semaglutide (generic Ozempic or Wegovy) for $199 ...

Novo Nordisk NVO announced that it has submitted a regulatory application to the European Medicines Agency (EMA) seeking ...

Africa's diabetes market is set to grow 7.2% annually, reaching $2.73 billion by 2025. Key trends include expanding CGM access, supporting local prod ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Stay Informed On Tariff Changes, Macroeconomic Trends, And More.” — The Business Research Company LONDON, GREATER LONDON, UNITED KINGDOM, June 30, 2025 /EINPresswire.com/ -- How Big Is The Global ...

Suzhou-based Innovent Biologics secured approval last week for its treatment mazdutide. Read more at straitstimes.com. Read ...

Novo Nordisk A/S and Eli Lilly & Co ... and safe as weekly injections peddled by Novo and Lilly. Leading insulin producer Gan & Lee Pharmaceutical is pushing ahead a longer-acting drug that can be ...

Novo Nordisk A/S (NYSE:NVO) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company discontinued its partnership with Hims & Hers concerning selling its weight-loss ...

People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently approved only for type 2 diabetes, according to results from a small trial.

Novo Nordisk is partnering with WeightWatchers to offer consumers access to Wegovy after it abruptly ended its collaboration with Hims & Hers.

Novo Nordisk plans to expand access to Wegovy through a collaboration with WeightWatchers, days after ending a partnership with telehealth firm Hims & Hers to sell the weight-loss drug.